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The kinetics of effector CD8-T-cell responses to specific Trypanosoma cruzi epitopes was investigated after
challenge. Our results suggest that the delayed kinetics differs from that observed in other microbial infections
and facilitates the establishment of the disease in naı¨ve mice. In contrast, in vaccinated mice, the swift
CD8-T-cell response helps host survival after challenge.
Major histocompatibility complex class Ia-restricted CD8
T cells are critical for the survival of naı¨ve and vaccinated mice
infected with the human protozoan parasite Trypanosoma cruzi
(1, 5, 9, 11, 15, 16, 18). The antiparasitic mechanisms mediated
by these cells are multiple, including cytokine secretion and
possibly direct cytotoxicity against infected cells (6, 12, 13). In
spite of their importance for host resistance, limited informa-
tion is available regarding the kinetics of effector CD8 T cells
following parasite challenge. Here, we describe studies aimed
at characterizing the kinetics of effector CD8-T-cell re-
sponses specific to epitopes present in the trans-sialidase (TS)
or the amastigote surface protein 2 (ASP-2), prime candidates
for vaccine development against Chagas’ disease (1, 4, 5, 18).
After infection with trypomastigotes of the Y strain, we
observed that the parasitemia of wild-type (WT) C57BL/6,
CD8 knockout (KO), gamma interferon (IFN-) KO, or per-
forin KO mice was not significantly different on day 8 after
challenge (peak parasitemia of WT mice). From days 9 to 13,
WT mice quickly reduced their parasitemia, and only 9% of
them died after challenge (Fig. 1A and B). In contrast, IFN-
KO mice were unable to control the parasitemia, dying faster
than the other mouse groups. CD8 KO or perforin KO mice
were unable to control their parasitemia at the same rate as
WT animals, dying between days 15 and 21 after challenge
(Fig. 1A and B). We concluded that IFN- secreted by non-
CD8 cells is important until day 13. CD8 cells and perforin
are critical for survival after day 14.
Based on the observations that CD8 cells, IFN-, and per-
forin are critical for mouse survival after challenge, we fol-
lowed the kinetics of specific effector CD8 T cells by using the
ex vivo enzyme-linked immunospot (ELISPOT) assay for
IFN- (4) and the in vivo cytotoxicity assay, which measures
the elimination of peptide-coated target cells mediated by per-
forin (3). Target cells were coated with synthetic peptides rep-
resenting the CD8 T-cell epitope IYNVGQVSI (TS) or VNH
RFTLV (ASP-2) (Table 1). The results of the in vivo cytotoxicity
assay were obtained by measuring the carboxyfluorescein diac-
etate succinimidyl diester-labeled cells in the spleens of recipient
mice (3). Identical results were seen when we analyzed labeled
cells in lymph nodes (data not shown).
In BALB/c mice, the in vivo cytotoxicity and IFN--secreting
cells specific to the TS peptide IYNVGQVSI were first de-
tected at the peak of parasitemia (day 9). Both T-cell activities
rose quickly until the 15th day and were kept high until the
30th day after infection. During the subsequent period, they
declined slowly but were still detectable by day 240 (Fig. 2A
and B).
A similar picture emerged when we evaluated the kinetics of
effector cells specific to the ASP-2 peptide VNHRFTLV. In
C57BL/6 mice, both T-cell activities were not detectable at the
peak of parasitemia (day 8). They rose quickly until the 16th
day and were kept high until the 60th day after infection.
During the subsequent period, both activities declined but
were still detectable by day 240 (Fig. 2C and D).
Treatment of T. cruzi-infected BALB/c or C57BL/6 mice
with anti-CD8 monoclonal antibody resulted in a selective de-
pletion of splenic CD8 T cells in vivo (98.6%) and a com-
plete reversion of the in vivo cytotoxicity response to the pep-
tide IYNVGQVSI or VNHRFTLV (Fig. 3A and B, respectively).
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TABLE 1. Peptides used in the present study





IYNVGQVSI TS 359–367 H-2Kd Trypomastigote 14
VNHRFTLV ASP-2 553–560 H-2Kb Amastigote 8
TEWETGQI ASP-2 320–327 H-2Kk Amastigote 1
a aa, amino acids.
b MHC, major histocompatibility complex.
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The phenotypes of splenic IFN--secreting cells were deter-
mined by sorting, with the aid of a FACS Vantage (Becton
Dickinson), CD8 cells costained with antibodies to CD62L
(anti-CD8-Pe-CY5, clone 53-67, and anti-CD62L-FITC, clone
Mel14; BD-Pharmingen) from C57BL/6 mice infected 80 days
earlier. ELISPOT assays performed with these purified cells
demonstrated that splenic IFN--secreting cells were CD8
CD62LLow (Fig. 4). Similar results had been described earlier
for mice infected with T. cruzi (Brazil strain) for more than 150
days (10).
Finally, we compared the kinetics of effector CD8-T-cell ex-
pansion following infection of immune or naı¨ve animals. C57BL/
6 or A/Sn mice were immunized with the plasmid pIgSPclone 9
(asp-2 gene) or with the recombinant protein gluthatione S-trans-
ferase (GST)-P4-P7, respectively (1, 4). After challenge, mice
vaccinated with plasmid pIgSPclone9 (C57BL/6) or with the re-
combinant protein GST-P4-P7 (A/Sn) quickly developed in vivo
specific cytotoxic cells against target cells coated with the peptide
VNHRFTLV or TEWETGQI, respectively (Fig. 5A and C).
Control mice injected with pcDNA3 or recombinant GST pre-
sented a delay in the generation of in vivo cytotoxicity.
The enumeration of specific CD8 T cells by ELISPOT
showed a similar pattern of immune response. After challenge,
mice vaccinated with the plasmid pIgSPclone9 or with the
recombinant protein GST-P4-P7 displayed faster expansion
and significantly higher numbers of IFN--secreting cells (Fig.
5B and D).
An interesting observation we made in naı¨ve mice was that
the expansion of specific splenic CD8 T cells occurred in the
days following the peak parasitemia, between days 9 and 15
after challenge of BALB/c or C57BL/6 mice. The delayed
kinetics of specific CD8-T-cell expansion may be an impor-
tant factor for the establishment of infection in naı¨ve hosts.
These results are in agreement with the data collected after the
challenge of naı¨ve KO mice. Mouse survival mediated by
CD8 T cells, perforin, and IFN- occurred mainly between
days 14 and 17 after challenge. This timing correlated closely
with the moment that specific effector CD8 T cells of C57BL/6
mice reached their maximum activity (days 15 and 16).
Overall, the kinetics of T. cruzi-specific CD8 cytotoxic T
cells differs sharply from the observations made with mice
infected with lymphocytic choriomeningitis virus, Listeria mono-
FIG. 1. Trypomastigote-induced parasitemia and mortality in WT, CD8 KO, IFN- KO, or perforin KO mice. Groups of mice were infected
intraperitoneally with 104 bloodstream trypomastigotes of the Y strain of T. cruzi. (A) Parasitemia was followed daily from days 5 to 13 after
challenge. The results represent the mean of five or six mice  standard deviation. The asterisks denote values statistically higher than the values
in control WT mice (P  0.05; one-way analysis of variance). The results are representative of two independent experiments. (B) Kaplan-Meier
curves for survival of each mouse group: (i) WT, n  32; (ii) CD8 KO, n  8; (iii) IFN- KO, n  12; (iv) perforin KO, n  16. The results were
pooled from two different experiments. Statistical analysis revealed significant differences in the survival of WT mice compared to the other mouse
groups (P  0.0001 in all cases; log rank test). CD8 KO and perforin KO mice survived longer than IFN- KO (P  0.01 in both cases).
FIG. 2. Kinetics of peptide-specific cell-mediated immune responses in BALB/c or C57BL/6 mice after challenge with trypomastigotes of T. cruzi.
BALB/c mice or C57BL/6 mice were challenged with 2.5 103 or 2.5 104 bloodstream trypomastigotes of T. cruzi, respectively. On the indicated
days, the parasitemia was monitored in these animals (closed symbols in all panels). The results represent the mean of six mice  standard
deviation (SD). (A) The in vivo cytotoxic activity of BALB/c mice against target cells coated with peptide IYNVGQVSI was determined (open
symbols). The results represent the mean of three to nine mice  SD per group. (B) IFN--producing spleen cells of BALB/c mice specific to the
peptide IYNVGQVSI were estimated by the ELISPOT assay (4). The results represent the mean number of spot-forming cells (SFC) per 106
splenocytes  SD (n  4; open symbols). (C) The in vivo cytotoxic activity of C57BL/6 mice against target cells coated with peptide VNHRFTLV
was determined. The results represent the mean of three or four mice  SD per group (open symbols). (D) IFN--producing spleen cells of
C57BL/6 mice specific to the peptide VNHRFTLV were estimated by the ELISPOT assay. The results represent the mean number of SFC per
106 splenocytes  SD (n  4; open symbols). The results are representative of two or more independent experiments.
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cytogenes, and Plasmodium yoelli. In these cases, maximum
CD8-T-cell immune response was achieved between days 4
and 8 following challenge and rapidly declined after that pe-
riod (2, 17, 19). Studies of mice infected with 	-galactosidase-
transgenic Toxoplasma gondii described much slower kinetics
(7). The distinct kinetics can be explained by differences in the
natures of these infections (acute versus chronic).
As opposed to naı¨ve mice, vaccinated immune animals ex-
hibited a significantly faster in vivo cytotoxic immune response.
This swift immune response correlated with protective immu-
nity, helping host survival after challenge.
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